New radiation method aims to ease gut pain for cancer patients
NCT ID NCT06778408
First seen Feb 05, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This study tests a new way of giving palliative radiation (HART) to people with metastatic cancer. The goal is to see if it causes fewer stomach and bowel side effects than standard radiation. About 103 adults with cancer that has spread will receive HART to bones or soft tissues in the chest, belly, or pelvis. Researchers will track side effects and quality of life for four weeks after treatment starts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER (DIFFERENT SOLID TUMOUR TYPES) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Vermont Medical Center
RECRUITINGBurlington, Vermont, 05401, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hybrid Palliative Radiation Therapy (HART)
What this could lead to
If successful, HART could become a standard way to deliver palliative radiation with fewer gut-related side effects, improving quality of life for people with metastatic cancer.
What could go wrong
This is a small, single-center phase II trial without a control group, so results may not be widely applicable. The technique may not reduce toxicity as hoped, or other side effects could emerge.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.